GPRC5D (Talquetamab Biosimilar) Recombinant Monoclonal Antibody

This recombinant monoclonal antibody is a research-grade biosimilar to talquetamab, designed to specifically target G protein-coupled receptor class C group 5 member D (GPRC5D). GPRC5D is an orphan receptor predominantly expressed on the surface of plasma cells and malignant plasma cells in multiple myeloma, while showing limited expression in normal tissues. This restricted expression pattern makes GPRC5D an attractive therapeutic target for hematological malignancies. The receptor plays a role in cellular signaling pathways, and its overexpression in multiple myeloma cells has been associated with disease progression and poor prognosis.

Talquetamab is a bispecific T-cell engager antibody that has demonstrated significant clinical efficacy in relapsed or refractory multiple myeloma by redirecting T cells to eliminate GPRC5D-expressing malignant cells. This biosimilar antibody serves as a valuable research tool for investigating GPRC5D biology, understanding mechanisms of action in multiple myeloma pathogenesis, evaluating immune-mediated cytotoxicity, and supporting preclinical studies in oncology and immunotherapy development. It enables researchers to explore novel therapeutic strategies targeting plasma cell disorders.